Chief Executive Officer

Chief Information Security Officer

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Roivant to report financial results for the second quarter ended September 30, 2025, and provide business update on Monday, November 10, 2025

Poxel: Availability of a First Document in Response to Questions Received From Shareholders

IT Business Partner - R&D

Roivant Sciences is a biopharmaceutical company focused on accelerating the development and commercialization of impactful medicines. The IT Business Partner for R&D will lead the technology strategy, implementation, and operational support for R&D applications, acting as a key liaison for all IT matters related to clinical, regulatory, safety, and quality projects.

Sign up with Google

Sign in with Google